Kiora Pharmaceuticals: Global KIO-301 Partnerships and Advancing ABACUS-2 Study Support Buy Rating with Unchanged $12 Price Target
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Michael Okunewitch maintains a Buy rating on Kiora Pharmaceuticals (KPRX) with an unchanged $12 price target. The recommendation is supported by KIO-301's global partnerships, including a new South Korean deal with Chong Kun Dang and existing agreements with Théa and Senju. These collaborations position the asset for coordinated Phase 3 development in retinitis pigmentosa, offering upfront payments and royalty potential. Additionally, the advancing ABACUS-2 study and recent stock price increase reinforce the favorable risk-reward profile.
In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Kiora Pharmaceuticals, with a price target of $12.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Michael Okunewitch has given his Buy rating due to a combination of factors tied to Kiora’s progress with KIO-301 and its partnering strategy. He points to the newly signed South Korean licensing deal with Chong Kun Dang alongside existing agreements with Théa and Senju as evidence that multiple regional players see commercial promise in KIO-301, reinforcing confidence in the asset’s potential and management’s execution.
He also highlights that these agreements collectively position KIO-301 for coordinated global Phase 3 development in retinitis pigmentosa, while providing Kiora with upfront payments, milestone opportunities, and future royalty streams. In his view, this growing network of partnerships, coupled with the advancing ABACUS-2 study and unchanged $12 price target, supports a favorable risk‑reward profile that justifies maintaining a Buy recommendation on the stock.
KPRX’s price has also changed moderately for the past six months – from $1.980 to $2.620, which is a 32.32% increase.